Hampton, UK – 5 June 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this role, Clive will be responsible for building the UK’s vaccine response to Covid-19.
Jonny Ohlson, Touchlight’s founder and CEO, commented: “With over 30 years of experience in life science research, including more than 20 in senior pharma positions, Clive has worked at the forefront of vaccine discovery and development. He has been Chairman of Touchlight for 10 years, providing invaluable guidance into the development of our platform and pipeline, which includes both prophylactic and therapeutic vaccines.
“Clive is a visionary with extraordinary insights into vaccine development. We are convinced that he is the right person to take forward the Covid-19 vaccine initiative in the UK.”
High-resolution images are available on request.
About Dr. Clive Dix
Dr. Dix has more than 30 years’ experience in life science research. He has spent over 20 years in senior pharmaceutical industry positions and has been at the forefront of vaccine discovery and development.
Previously, Clive was the Co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006. Before that, he was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until it was acquired by Chiron Vaccines in 2003. Clive began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he ultimately held the position of UK Research Director.
Clive has previously been Chairman of the BioIndustry Association, and currently, as well as being Chairman of Touchlight, he is Non-Executive Chairman of Centauri Ltd, Chief Executive Officer of C4X Discovery plc and a Non-Executive Director of the Medicines Discovery Catapult.
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
For more information, please visit our website, www.touchlight.com, or connect with us on LinkedIn.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact: firstname.lastname@example.org